Rosen Law Firm Advises Applied Therapeutics Investors Ahead of Class Action Deadline

NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, known for its global work in investor rights, is reaching out to individuals who invested in securities of Applied Therapeutics, Inc. (NASDAQ: APLT) during the period between January 3, 2024, and December 2, 2024 (referred to as the "Class Period"). There is an urgent reminder of the upcoming lead plaintiff deadline on February 18, 2025.

Understanding the Importance: Investors who bought Applied Therapeutics securities during the Class Period might be eligible for compensation without incurring any out-of-pocket fees. This is possible through a contingency fee arrangement, which means that legal fees are paid only if the case is successful.

Next Steps for Investors: To participate in the class action against Applied Therapeutics, individuals are encouraged to visit this link, call Phillip Kim, Esq. at 866-767-3653, or email [email protected] for detailed information. A class action lawsuit is already underway, and those interested in serving as lead plaintiff must act and file their motion by February 18, 2025. The lead plaintiff represents the interests of all class members during the litigation process.

Why Choose Rosen Law Firm: Investors are urged to select legal counsel that has a proven record of success in leadership positions within class action lawsuits. It is important to be cautious because many firms that distribute notices may lack the necessary experience or peer recognition in litigating securities class actions. Many of these firms serve only as intermediaries, working with other firms that actually handle the litigation. Rosen Law Firm has represented investors worldwide, focusing on securities class actions and shareholder derivative cases. They hold a notable achievement of securing the largest securities class action settlement against a Chinese company at the time. In 2017, the firm was ranked No. 1 by ISS Securities Class Action Services for the highest number of class action settlements, and it has continued to rank among the top firms since then. Over the years, Rosen Law Firm has successfully recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone. Additionally, the founding partner, Laurence Rosen, received recognition as a Titan of the Plaintiffs' Bar by Law360 in 2020, and many attorneys in the firm have been acknowledged by Lawdragon and Super Lawyers.

Case Details: The class action lawsuit against Applied Therapeutics claims that statements made during the Class Period were misleading. Specifically, the lawsuit alleges that the company concealed important information regarding the clinical trial protocols they had in place, leading investors to unknowingly believe that proper practices were being followed. In reality, it is asserted that Applied Therapeutics failed to adhere to the necessary clinical trials and practices, which put the validity of their trial data in jeopardy with the U.S. Food and Drug Administration (FDA) in relation to a New Drug Application. When the truth was revealed, it allegedly caused significant financial harm to investors.

Potential class members who are interested in participating in the action against Applied Therapeutics should still be aware that no class has been formally certified yet. Until that happens, individuals are not represented by any counsel unless they choose to hire one. Investors have the option to select their legal representation or remain as absent class members, without taking any action at this stage. An individual’s chances of obtaining any potential recovery in the future are not influenced by their status as a lead plaintiff.

Stay updated with news about the case by following Rosen Law Firm on LinkedIn, on Twitter, or on Facebook.

This notice serves as an attorney advertisement. Past results do not ensure similar outcomes in future cases.

lawsuit, investment, classaction